Heart Failure-USB: Prediction and Progression
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Basel, Switzerland
About this trial
This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients hospitalized with a primary diagnosis of ACS
Patients hospitalized with a primary or secondary diagnosis of AHF
Disqualifiers
Existence of a documented statement of the patient against the scientific use of clinical data
Trial population
Patients that were hospitalized at the Universitätsspital Basel/ Switzerland with the diagnosis of ACS or AHF during the years 2010 - 2023
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
medical chart review
Other interventiondata generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
data generated by direct IT export
Other interventiondata generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
Treatment groups
6,000 Participants
are divided into 2 treatment groupsGroup A: acute coronary syndrome (ACS)2 interventions
Group B: acute heart failure (AHF)2 interventions
Trial outcomes
Primary outcomes
1
number of all-cause death
number of all-cause death in patients hospitalized with ACS and AHF during the years 2010-2023.
Time frame
1 to 8 years after hospitalization2
number of HF hospitalizations
number of new HF hospitalizations in patients hospitalized with ACS and AHF during the years 2010-2023
Time frame
1 to 8 years after hospitalization3
number of cardiovascular death
number of cardiovascular death in patients hospitalized with ACS and AHF
Time frame
1 to 8 years after hospitalization4
number of cardiovascular hospitalizations
number of cardiovascular hospitalizations
Time frame
1 to 8 years after hospitalizationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov